



Research Article

ISSN : 0975-7384  
CODEN(USA) : JCPRC5

## Synthesis and spectral studies of noval benzyl derivative of ciprofloxacin and their Cu (II) and Co (II) complexes

Y.M. Thakre<sup>1</sup> and M. D. Choudhary<sup>2</sup>

<sup>1</sup>Department of Applied Chemistry of Engineering, DMIETR, Sawangi, Wardha

<sup>2</sup>Department of Applied Chemistry of Engineering, BDCOE, Sevagram, Wardha

---

### ABSTRACT


Reaction of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7- (1-piperazinyl)-3quinolone carboxylic acid (ciprofloxacin) with The benzyl chloride in presence of base triethylamine, with introduction of amide group in ciprofloxacin to form new benzyl derivative of 1-cyclopropyl-6-fluoro-4-oxo-7-[4-(phenyl carbonyl) piperazin-1-yl]-1,4-dihydroquinoline-3-carboxylic acid (Cip-d) and their Cu(II) and Co(II) complexes were established on the basis of spectral studies <sup>1</sup>HNMR, IR, Mass spectroscopy .

**Key Words:** Ciprofloxacin Derivative (Cip.D), Synthesis, Antimicrobial activity.

---

### INTRODUCTION

The emergence of bacterial resistance to different classes of antibacterial agents, such as B-lactams, quinolones, fluoroquinolones and macrolides, is an alarming problem that seriously affects human health <sup>[1]</sup>. To combat this situation, numerous efforts have been made in the development of new approaches to treat bacterial infections, particularly for therapeutics with novel mechanisms of action and little or no cross resistance <sup>[2, 4]</sup>. As a result, new antibacterial agents against hospital-acquired Gram-positive bacterial pathogens<sup>[5]</sup>, especially against methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), have become the centre of attention in this highlighted research field <sup>[6]</sup>. Ciprofloxacin hydrochloride, second-generation quinolone antibiotic, is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase and topoisomerase IV, enzymes necessary to separate bacterial DNA, thereby inhibiting cell division <sup>[1]</sup>. Ciprofloxacin has been approved for the treatment of infections, especially urinary tract infections, prostatitis, shigellosis <sup>[7, 8, 9]</sup>. It has also been found to show anti-tumour activity against P388 leukemia (Yamashita et al., 1992). Ciprofloxacin is a quinolone drug having a bicyclic ring structure having a carbonyl group at position 3, a keto at position 4, a fluorine atom at position 6 and a nitrogen heterocyclic moiety at 7 position. The nature of the substituent at C-7 position has a great effect on potency, spectrum, solubility and pharmacokinetics. Ciprofloxacin has a nitrogen heterocyclic linked to the C-7 position of the quinolone ring through the heterocyclic nitrogen<sup>[10,11]</sup>. Extensively investigate the substituent at N-H in piperazine respect significant modification. Structure of Cip-D is as follows. Early we isolated the Cip-D by the reaction of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7- (1-piperazinyl)-3quinolone carboxylic acid (ciprofloxacin) with the 4-methoxy benzyl chloride in presence of base triethylamine, with introduction of an amide group in ciprofloxacin to form the derivative 1-cyclopropyl-6-fluoro-4-oxo-7-[4-(phenyl carbonyl) piperazin-1-yl]-1,4-dihydroquinoline-3-carboxylic acid (Cip-D)<sup>[12]</sup>.



**Figure 1; Synthesis of ciprofloxacin Derivative(Cip-D)**

## EXPERIMENTAL SECTION

### (a)Regeneration of free ciprofloxacin:-

A solution of ciprofloxacin hydrochloride (10 g) in water (50 ml) was treated with excess of 5% aqueous sodium bicarbonate solution resulting in the formation of white precipitates which were filtered through suction filtration and left to dry as a neutral ciprofloxacin (8.3 & 83%).

### (b)Procedure for ciprofloxacin derivative

Ciprofloxacin was dissolved in one molar equivalent of appropriate 4-methoxy 1-chlorobenzene and the resulting mixture was refluxed. The product was analysed by TLC. Cool the resultant mixture, remove excess solvent in vacuum and residue was suspended in brine and extracted with dichloromethane (3x50) the organic phase was dried over  $\text{CaCl}_2$  and evaporated in presence of chloroform to afford the solid product in pure form.

### (c)Complexes of Copper acetate [ $\text{Cu}_2(\text{Cip.D})_2$ ]-

Take 1 gm copper acetate (1mM) (anhydrous). Dissolved in 5ml ethanol and 5ml distilled water. Now take 0.872 gm (2mM) cip-d in 5ml ethanol and 5ml distilled water. Add sol<sup>n</sup> of copper acetate (1mM) drop by drop with constant stirring in solution of Cip-D. Solid complex digested on water bath at 60°C. On cooling pass through filter paper. Wash with 50% alcohol.

### (d)Complex Cobalt-[Co (Cip.D) <sub>2</sub>]

Take 1 gm Cobalt nitrate (1mM) (anhydrous). Dissolved in 5ml ethanol and 5ml distilled water. Now take 0.872 gm (2mM) Cip-d in 5ml ethanol and 5ml distilled water. Add sol<sup>n</sup> of copper acetate (1mM) drop by drop with constant stirring in solution of cip-d. pH of sol<sup>n</sup> was maintained 6.0-6.5 by HCl and  $\text{NH}_4\text{OH}$ . Reflux for an hour, yellow coloured complex was formed. It was filtered, dried in air, recrystallised from chloroform. Wash with 50% alcohol.

## RESULTS AND DISCUSSION

The structure of the synthesized compound was established on the basis of IR and NMR spectra data and elemental analysis as shown in table (1,2). Cip-D isolated by the reaction of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolone carboxylic acid (ciprofloxacin) with benzyl chloride in presence of base triethylamine, with introduction of amide group in ciprofloxacin to form derivative 1-cyclopropyl-6-fluoro-4-oxo-7-[4-(phenyl carbonyl) piperazin-1-yl]-1,4-dihydroquinoline-3-carboxylic acid (Cip-D) and their complexes of Cu(II) and Co(II). The carbonyl  $\text{C}=\text{O}$  stretch was absent in Cip-D complexes of Cu and Co at the region of 1724.35, which is present in Cip-D, shows the bonding through  $\text{C}=\text{O}$  stretch. Similarly five extra peaks at 7.589, 7.613, 7.941, 7.964, 7.985 (m, 5H) show the substitution of benzoyl group in cip-D [H-9, 10, 11, 12 and 13]. <sup>1</sup>H NMR study of Cu(II) and Co(II) metal ion with ciprofloxacin derivative (Cip-D) shows slight shift of H-5. In Cip-D the peak was observed at 8.673 (s, 1H) while in complex of Cu(II) and Co(II) it shifted to higher position at 10.220 (s, 1H) because of bonding with metal ion.




Fig-2 (a)Cip-D,(b)Cip-D complexes.

## Element analysis


Sr.No	M.P	Mol.wt	Molecular formula	Element analysis		
				C	H	N
Ciprofloxacin	255-257	331.34	C <sub>17</sub> H <sub>18</sub> FN <sub>3</sub> O <sub>3</sub>	61.623360	5.475509	12.681645
Cip-d	274	435.44	C <sub>24</sub> H <sub>22</sub> FN <sub>3</sub> O <sub>4</sub>	66.198358	5.092303	9.649729
[Cu <sub>2</sub> (Cip.D) <sub>2</sub> ]	269-271	933.448	C <sub>48</sub> H <sub>43</sub> F <sub>2</sub> N <sub>6</sub> O <sub>8</sub> Cu	65.782686	4.830312	3.196379
[Co (Cip.D) <sub>2</sub> ]	266-267	928.835	C <sub>48</sub> H <sub>43</sub> F <sub>2</sub> N <sub>6</sub> O <sub>8</sub> Co	66.130749	4.855870	3.213291

TABLE -2

Sr. No	Name of compound	IR	<sup>1</sup> H-NMR
1.	Ciprofloxacin	Spectra of ciprofloxacin at 1724.35 c; C=O stretch of Keton at 1624.99 cm <sup>-1</sup> ; 3099.35 cm <sup>-1</sup> assigned C-Hstr.CH2	1.296 (m-2H)-H 8, 8'; 1.339(t-2H)-H, 7-7'; 2.892(t-4H)-H 1-1,3.210(t, 4H)-H2-2,3.386(m, 1H) H-6,8.673(S, 1H)-H-5,7.852(d, 1H)-H-4,7.501(d, 1H)-H-3,
2.	Cip-d	3527-3207 cm <sup>-1</sup> O-H stretch; 3180.4 cm <sup>-1</sup> C-H stretch of aromatic; 3051 cm <sup>-1</sup> C-H stretch of CH2; 2854.45 cm <sup>-1</sup> for C-H stretch of CH <sub>3</sub> ; C=O Carboxylic acid is 1720.39 cm <sup>-1</sup> .C=O Keton in 1616.24 cm <sup>-1</sup>	1.274 (m-2H)-H 8, 8'; 1.333(t-2H)-H, 7-7'; 3.010(t-4H)-H 1-1, 3.125(t, 4H)-H2-2; 3.286(m, 1H) H-6 ;8.673(S, 1H)-H-5; 7.920(d, 1H)-H-4; 7.479 (d, 1H)-H-3; 7.589, 7.613, 7.941, 7.964, 7.985(m, 5H) [H-9, 10, 11, 12 and13 (Benzoyl group)].
3.	Cu	3083.53 cm <sup>-1</sup> is of C-H stretch of aromatic; 2916.38 cm <sup>-1</sup> is the C-H stretch of CH2.2804.45 cm <sup>-1</sup> is the band for C-H stretch of CH <sub>3</sub> of Keton in 1629.77	2.500(t-4H)-H 1-1,1.240 (m-2H)-H 8, 8';3.344 (m, 1H) H- 6, 7.857, 7.436, 7.357, 7.354, 7.350, (m,5H)(Benzoyl group),
4.	CO	3082.13 cm <sup>-1</sup> is of C-H stretch of aromatic; 2915.12 cm <sup>-1</sup> is the C-H stretch of CH2; 2804.45 cm <sup>-1</sup> is the band for C-H stretch of CH <sub>3</sub> ; Keton in 1629.17	1.274 (m-2H)-H 8, 8'; 1.333(t-2H)-H, 7-7'; 3.010(t-4H)-H 1-1, 3.125(t, 4H)-H2-2; 3.286(m, 1H) H-6 ;8.673(S, 1H)-H-5; 7.920(d, 1H)-H-4; 7.479 (d, 1H)-H-3; 7.589, 7.613, 7.941, 7.964, 7.985(m, 5H) [H-9, 10, 11, 12 and13 (Benzoyl group)].

## Mass Spectrum:

The molecular ion peak is observed at m/z 436 corresponding to the calculated molecular weight of the Cip.D. The other peak at m/z 418,391.43, 312,231.09,210 also observed.



Mass Fragmentation of Cip.D.

Fig.4-1H-NMRCIP-D





Fig.3-1H-NMR of Ciprofloxacin



### Acknowledgments

Author is thankful to Datta Meghe Institute of Engineering and Technology, Sawangi (Meghe), Wardha, IIT Bombay for their help in spectra analysis.

### REFERENCES

- [1] H. Goossens, M. Ferech, R. Vander Stichele, M Raj, Monique Elsevier. *Lancet*. **2005**; 365:579-87
- [2] T.A .Davies, R .Goldschmidt, S. P.Fleger, M. Loeloff, , *J Antimicrob Chemother* **2003**; 52:168–175.
- [3] B .Ann, D.Pharm, W.Christopher ,T. Cheryle Gurk,Proc (Bayl Univ Med Cent). **2000** July; 13(3): 289–292.
- [4] R.J.Fass, J.Barnishan , L.W. Ayers ,*J Antimicrob Chemother*. **1995** Aug;36(2):343-53.
- [5] D.C. Hooper ,*Lancet Infect Dis*. **2002** Sep; 2(9):530-8.
- [6] F. D. Lowy, *J Clin Invest*. **2003**; 111(9):1265–1273.
- [7] Cooke F.J. Wain J.**2004**. *Travel and Intact dir*. 2:67 – 74.
- [8] Fisher,J.F;Meroueh, S.O; Mobashery, S.*Chem Rev* **2005**, 105,395-424.
- [9] Sandhya, R.G; McColm, J.M; Tapin, P; Barrowcliffe, S; Hevizi, S. *Antimicrob Agent Chemother* **2004**, 48, 4835-4842.
- [10] Domagala,J.M;Heifetz,C.L;Hutt,M.P;Mich, T.F; Nichols J.B; Solomon M;Worth D, F, *J.Med.Chem*.**1988**, 31,991.
- [11] Chu, D.T.W,Femandes,P.B,Claiborne,A.K;Pihuleac,E;Nordeen,C.W;Maleczka,R.E;Pernet, A.G. *J .Med Chem*. **1985**, 28, 1558.
- [12] Thakre Y.M,Choudhary M.D, *J. Chem. Pharm. Res*, **2011**,3 (5):390-398.